Rifkin, Robert M.
Crawford, Jeffrey
Mahtani, Reshma L.
Dale, David C.
Narang, Mohit
MacLaughlin, William W.
Huynh, Chanh
Gawade, Prasad L.
Lewis, Sandra
DeCosta, Lucy
Lawrence, Tatiana
Belani, Rajesh
Funding for this research was provided by:
Amgen
Article History
Received: 13 January 2022
Accepted: 12 June 2022
First Online: 22 June 2022
Declarations
:
: An internal review board approved the prespecified study protocol before initiating recruitment. The investigators obtained informed consent from each participant or each participant’s legally acceptable representative.
: Written informed consent was obtained from all participants included in the study.
: Not applicable.
: Robert M. Rifkin reports participation in advisory boards for Amgen, BMS (Celgene), Coherus, Fresenius-Kabi, GSK, Janssen, and Pfizer. Jeffrey Crawford reports consulting fees from GlaxoSmithKline, G1 Therapeutics, Merck, Pfizer, Spectrum, and participation on a data safety monitoring board or advisory board for Beyond Spring, G1 Therapeutics, Merrimack, Mylan, and Roche. Reshma L. Mahtani reports consulting fees from Biotheranostics, Amgen, Agendia, Eisai, Immunomedics, Genentech, Lilly, Novartis, Merck, Pfizer, Puma, Sanofi, Seagen, AstraZeneca, Daiichi, and participation on an advisory board for AstraZeneca, Amgen, Agendia, Biotheranostics, Eisai, Immunomedics, Lilly, Novartis, Merck, Pfizer, Puma, Sanofi, Seagen, and Daiichi. David Dale reports consulting fees from Amgen, and contracted research support from Amgen. Sandra Lewis, Lucy DeCosta, and Tatiana Lawrence are employees and stockholders of Amgen. Prasad L. Gawade and Rajesh Belani were employees of Amgen; Rajesh Belani is an employee and a stockholder of Poseida Therapeutics. Mohit Narang, William W. MacLaughlin, and Chanh Huynh have no disclosures to report.